Back to search results

Study of Cannabidiol for Chronic Pain

This study is looking at how a high-cannabidiol (CBD), low-tetrahydrocannabinol (THC) product, called Cannabidiol (DRUG), affects chronic pain. Researchers want to see if this product can help reduce pain, change how much other pain medications people use, and improve overall well-being and quality of life. You might be able to join if you are 21 or older, speak English, and have chronic musculoskeletal pain like arthritis. The study will compare Cannabidiol (DRUG) to a placebo (an inactive substance that looks and tastes the same) over 9 weeks. The main goal is to see how much your pain ratings change after 6 weeks of treatment. The current status of this study is unclear, and it plans to enroll 25 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It will involve comparing Cannabidiol (DRUG) to a placebo product.
What's involved
Participants will be assessed at the beginning of the study and over 9 weeks of treatment. This includes measures of pain, medication use, and thinking abilities, and providing samples for analysis.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for measuring pain changes is at 6 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03984565

PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product

Recruiting
PHASE2Ages 21+InterventionalTreatment
Staci Gruber, Ph.D.
~25 participants
Updated 2026-03-30 on ClinicalTrials.gov
What's tested:CannabidiolPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in pain ratings on a Numerical Rating Scale (NRS)
Measured over 6 weeks

Conditions

Chronic Pain

Explore related trials

Chronic Pain

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Staci Gruber, Ph.D. · PRINCIPAL_INVESTIGATOR · Mclean Hospital

Who to contact

Staci Gruber, Ph.D.
[email protected]
617-855-2762
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subject has provided informed consent
Subject is 21 or older
Subject is fluent in English
Subject endorses a musculoskeletal chronic pain condition including, but not limited to, chronic pain due to injury, arthritis (including osteoarthritis and rheumatoid arthritis), bursitis, etc.

Exclusion

Non-fluent English speakers
Estimated IQ \< 75
A history of head injury or loss of consciousness greater than 5 minutes
Currently uses CBD products regularly
Female subjects will be excluded if they have a positive urine pregnancy test, are trying to become pregnant, or are currently breastfeeding
Presence of a serious or unstable medical illness, including liver, kidney, or cardiovascular disease (hyper/hypotension, cardiac disorders), or neurological disorder (including seizure disorder)
Primary neuropathic pain or cancer-related pain; patients experiencing neuropathic pain secondary to musculoskeletal pain will be allowed to enter the study
Disclosure of a genetic polymorphism affecting CYP2C9 function

What this trial measures

  • Change in pain ratings on a Numerical Rating Scale (NRS)6 weeks

    The NRS is an 11-point scale on which subjects rate their pain by choosing a number between 0 (no pain) and 10 (worst possible pain). Lower scores indicate less pain.